PredictImmune’s prognostic biomarker for inflammatory bowel disease (IBD) and the PROFILE study to feature at meetings on both sides of the Atlantic in November.
Cambridge, UK, 9th November 2018: There will be two opportunities to hear about PredictImmune’s ground-breaking development of the first prognostic biomarker test for IBD in the coming weeks, with presentations in Nottingham, UK and New York, USA.
The British Society of Gastroenterology’s Investigators Meeting 2018
East Midlands Conference Centre, Nottingham | Mon, 12th November, 10:00 – 17:00
Dr. Nurulamin Noor will be presenting an update of progress on PROFILE; the first biomarker stratified trial in Crohn’s disease at the fourth annual meeting of the UK’s IBD investigators. The IBD investigators meeting is open to all members of the IBD MDT, including nurses, trainees and trials managers, and provides a great opportunity to get up to date with all the latest studies in IBD.
IBD Innovate: Product Development for Crohn’s & Colitis
The New York Academy of Medicine | 13th November, 2018
PredictImmune’s VP Platform Delivery and Founder, Dr Paul Lyons will present at this exciting event in New York. The IBD Innovate conference is a new event convened by the Crohn’s and Colitis Foundation to showcase innovative product development programs in IBD and is expected to become the premier product development event in the field of IBD. PredictImmune’s prognostic biomarker for IBD is a perfect fit for this innovative meeting as it leads progress towards a future of personalised medicine in IBD.
The Crohn’s & Colitis Foundation seeks to accelerate the discovery and development of novel products with the potential to address the unmet medical needs of IBD.
For information: www.predictimmune.com
+44 (0)1223 804 195